Nvidia AI Agents Power Drug Discovery for Certara, Silo

Certara is integrating Nvidia’s BioNeMo Agent Toolkit into its AI-driven drug development platform. This partnership aims to combine Certara's scientific software and data with AI-first frameworks. The BioNeMo Agent Toolkit will help turn AI agents into autonomous life sciences researchers. These specialized AI agents will analyze scientific models and datasets across different stages of drug development. They can optimize dosing strategies, analyze clinical data, and simulate patient scenarios. Certara says this technology will accelerate insight generation for biosimulation experts. Separately, Silo Pharma's subsidiary, QwikAgents, has joined the Nvidia Developer Program. QwikAgents automates complex workflows using autonomous AI agents. Joining the program gives QwikAgents access to Nvidia’s AI software ecosystem and development resources. This will help them expand AI agent capabilities for enterprise customers. These developments show how AI agents are being used to advance drug discovery and other complex tasks.